PGNY Quote, Financials, Valuation and Earnings

Clover Health Investments has a net margin of 4.65% compared to Progyny's net margin of -0.28%. Progyny's return on equity of 11.16% beat Clover Health Investments's return on equity of -7.67%.

Progyny has a consensus price target of $26.25, signalling upside risk potential of 23.59%. On the other hand Clover Health Investments has an analysts' consensus of $4.69 which suggests that it could grow by 80.99%. Given that Clover Health Investments has higher upside potential than Progyny, analysts believe Clover Health Investments is more attractive than Progyny.

Progyny has a beta of 1.307, which suggesting that the stock is 30.703% more volatile than S&P 500. In comparison Clover Health Investments has a beta of 1.861, suggesting its more volatile than the S&P 500 by 86.075%.

Progyny has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Clover Health Investments offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny pays -- of its earnings as a dividend. Clover Health Investments pays out -- of its earnings as a dividend.

Progyny quarterly revenues are $324M, which are smaller than Clover Health Investments quarterly revenues of $462.3M. Progyny's net income of $15.1M is higher than Clover Health Investments's net income of -$1.3M. Notably, Progyny's price-to-earnings ratio is 37.26x while Clover Health Investments's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny is 1.64x versus 0.86x for Clover Health Investments. Usually stocks with elevated PS ratios are considered overvalued.

NeueHealth has a net margin of 4.65% compared to Progyny's net margin of -5.44%. Progyny's return on equity of 11.16% beat NeueHealth's return on equity of -3241.93%.

Progyny has a consensus price target of $26.25, signalling upside risk potential of 23.59%. On the other hand NeueHealth has an analysts' consensus of $7.00 which suggests that it could grow by 2.04%. Given that Progyny has higher upside potential than NeueHealth, analysts believe Progyny is more attractive than NeueHealth.

Progyny has a beta of 1.307, which suggesting that the stock is 30.703% more volatile than S&P 500. In comparison NeueHealth has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Progyny has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeueHealth offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny pays -- of its earnings as a dividend. NeueHealth pays out -- of its earnings as a dividend.

Progyny quarterly revenues are $324M, which are larger than NeueHealth quarterly revenues of $215.8M. Progyny's net income of $15.1M is higher than NeueHealth's net income of -$11.7M. Notably, Progyny's price-to-earnings ratio is 37.26x while NeueHealth's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny is 1.64x versus 0.06x for NeueHealth. Usually stocks with elevated PS ratios are considered overvalued.

Oscar Health has a net margin of 4.65% compared to Progyny's net margin of 9.04%. Progyny's return on equity of 11.16% beat Oscar Health's return on equity of 10.83%.

Progyny has a consensus price target of $26.25, signalling upside risk potential of 23.59%. On the other hand Oscar Health has an analysts' consensus of $17.43 which suggests that it could grow by 4.88%. Given that Progyny has higher upside potential than Oscar Health, analysts believe Progyny is more attractive than Oscar Health.

Progyny has a beta of 1.307, which suggesting that the stock is 30.703% more volatile than S&P 500. In comparison Oscar Health has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Progyny has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oscar Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Progyny pays -- of its earnings as a dividend. Oscar Health pays out -- of its earnings as a dividend.

Progyny quarterly revenues are $324M, which are smaller than Oscar Health quarterly revenues of $3B. Progyny's net income of $15.1M is lower than Oscar Health's net income of $275.3M. Notably, Progyny's price-to-earnings ratio is 37.26x while Oscar Health's PE ratio is 59.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny is 1.64x versus 0.45x for Oscar Health. Usually stocks with elevated PS ratios are considered overvalued.

UnitedHealth Group has a net margin of 4.65% compared to Progyny's net margin of 5.74%. Progyny's return on equity of 11.16% beat UnitedHealth Group's return on equity of 21.74%.

Progyny has a consensus price target of $26.25, signalling upside risk potential of 23.59%. On the other hand UnitedHealth Group has an analysts' consensus of $385.25 which suggests that it could grow by 25.26%. Given that UnitedHealth Group has higher upside potential than Progyny, analysts believe UnitedHealth Group is more attractive than Progyny.

Progyny has a beta of 1.307, which suggesting that the stock is 30.703% more volatile than S&P 500. In comparison UnitedHealth Group has a beta of 0.449, suggesting its less volatile than the S&P 500 by 55.115%.

Progyny has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UnitedHealth Group offers a yield of 2.77% to investors and pays a quarterly dividend of $2.21 per share. Progyny pays -- of its earnings as a dividend. UnitedHealth Group pays out 52.29% of its earnings as a dividend. UnitedHealth Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Progyny quarterly revenues are $324M, which are smaller than UnitedHealth Group quarterly revenues of $109.6B. Progyny's net income of $15.1M is lower than UnitedHealth Group's net income of $6.3B. Notably, Progyny's price-to-earnings ratio is 37.26x while UnitedHealth Group's PE ratio is 12.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Progyny is 1.64x versus 0.69x for UnitedHealth Group. Usually stocks with elevated PS ratios are considered overvalued.